Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea

Ki Bong Yoo, Sang Gyu Lee, Sohee Park, Tae Hyun Kim, Jeonghoon Ahn, Mee Hyun Cho, Eun Cheol Park

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives: To evaluate the quantitative effects of the drug price reduction on pharmaceutical expenditures and the new guidelines to restrict prescribing on drug utilisation for antihypertensive drugs. Design: We used an interrupted time series design with the National patient sample data of Health Insurance Review and Assessment Service in South Korea. Methods: 54 295 participants who were with primary hypertension from the National patient sample data of Health Insurance Review and Assessment Service were included. The study period was from March 2011 to December 2013. The dependent variables were antihypertensive drug costs, antihypertensive drug cost per prescribing day, daily drug utilisation, average number of drugs per month, percentage of original drugs per prescription, drug overutilisation and prohibited combinations. Segmented regression analysis was used. Results: The drug price reduction reduced expenditure (US$-1.51, -10.2%), and the new guidelines reduced expenditures even more (US$ -2.13; -16.2%). These policies saved US$4.22 (28%) of antihypertensive drug costs per patient in December 2013 compared to March 2012. Drug price reduction policy was introduced in April 2012. We established the policy effect by comparing it before (March 2012) with after(21 months later-December 2012). The effects of the guidelines decreased expenditures, daily drug utilisation and the average number of drugs per month more than did the drug price reduction. Conclusions: Both policies saved money. The guidelines were more effective over time and had fewer side effects such as increasing daily drug utilisation and number of drugs than the effects of drug price reduction.

Original languageEnglish
Article numbere006940
JournalBMJ open
Volume5
Issue number7
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Korea
Health Expenditures
Antihypertensive Agents
Drug Utilization
Pharmaceutical Preparations
Drug Costs
Guidelines
Health Insurance
Drug Prescriptions
Republic of Korea
Regression Analysis
Hypertension

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Yoo, Ki Bong ; Lee, Sang Gyu ; Park, Sohee ; Kim, Tae Hyun ; Ahn, Jeonghoon ; Cho, Mee Hyun ; Park, Eun Cheol. / Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea. In: BMJ open. 2015 ; Vol. 5, No. 7.
@article{e0cd7f077f2c42e5851fd229e1ec1f2a,
title = "Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea",
abstract = "Objectives: To evaluate the quantitative effects of the drug price reduction on pharmaceutical expenditures and the new guidelines to restrict prescribing on drug utilisation for antihypertensive drugs. Design: We used an interrupted time series design with the National patient sample data of Health Insurance Review and Assessment Service in South Korea. Methods: 54 295 participants who were with primary hypertension from the National patient sample data of Health Insurance Review and Assessment Service were included. The study period was from March 2011 to December 2013. The dependent variables were antihypertensive drug costs, antihypertensive drug cost per prescribing day, daily drug utilisation, average number of drugs per month, percentage of original drugs per prescription, drug overutilisation and prohibited combinations. Segmented regression analysis was used. Results: The drug price reduction reduced expenditure (US$-1.51, -10.2{\%}), and the new guidelines reduced expenditures even more (US$ -2.13; -16.2{\%}). These policies saved US$4.22 (28{\%}) of antihypertensive drug costs per patient in December 2013 compared to March 2012. Drug price reduction policy was introduced in April 2012. We established the policy effect by comparing it before (March 2012) with after(21 months later-December 2012). The effects of the guidelines decreased expenditures, daily drug utilisation and the average number of drugs per month more than did the drug price reduction. Conclusions: Both policies saved money. The guidelines were more effective over time and had fewer side effects such as increasing daily drug utilisation and number of drugs than the effects of drug price reduction.",
author = "Yoo, {Ki Bong} and Lee, {Sang Gyu} and Sohee Park and Kim, {Tae Hyun} and Jeonghoon Ahn and Cho, {Mee Hyun} and Park, {Eun Cheol}",
year = "2015",
month = "1",
day = "1",
doi = "10.1136/bmjopen-2014-006940",
language = "English",
volume = "5",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "7",

}

Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea. / Yoo, Ki Bong; Lee, Sang Gyu; Park, Sohee; Kim, Tae Hyun; Ahn, Jeonghoon; Cho, Mee Hyun; Park, Eun Cheol.

In: BMJ open, Vol. 5, No. 7, e006940, 01.01.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea

AU - Yoo, Ki Bong

AU - Lee, Sang Gyu

AU - Park, Sohee

AU - Kim, Tae Hyun

AU - Ahn, Jeonghoon

AU - Cho, Mee Hyun

AU - Park, Eun Cheol

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: To evaluate the quantitative effects of the drug price reduction on pharmaceutical expenditures and the new guidelines to restrict prescribing on drug utilisation for antihypertensive drugs. Design: We used an interrupted time series design with the National patient sample data of Health Insurance Review and Assessment Service in South Korea. Methods: 54 295 participants who were with primary hypertension from the National patient sample data of Health Insurance Review and Assessment Service were included. The study period was from March 2011 to December 2013. The dependent variables were antihypertensive drug costs, antihypertensive drug cost per prescribing day, daily drug utilisation, average number of drugs per month, percentage of original drugs per prescription, drug overutilisation and prohibited combinations. Segmented regression analysis was used. Results: The drug price reduction reduced expenditure (US$-1.51, -10.2%), and the new guidelines reduced expenditures even more (US$ -2.13; -16.2%). These policies saved US$4.22 (28%) of antihypertensive drug costs per patient in December 2013 compared to March 2012. Drug price reduction policy was introduced in April 2012. We established the policy effect by comparing it before (March 2012) with after(21 months later-December 2012). The effects of the guidelines decreased expenditures, daily drug utilisation and the average number of drugs per month more than did the drug price reduction. Conclusions: Both policies saved money. The guidelines were more effective over time and had fewer side effects such as increasing daily drug utilisation and number of drugs than the effects of drug price reduction.

AB - Objectives: To evaluate the quantitative effects of the drug price reduction on pharmaceutical expenditures and the new guidelines to restrict prescribing on drug utilisation for antihypertensive drugs. Design: We used an interrupted time series design with the National patient sample data of Health Insurance Review and Assessment Service in South Korea. Methods: 54 295 participants who were with primary hypertension from the National patient sample data of Health Insurance Review and Assessment Service were included. The study period was from March 2011 to December 2013. The dependent variables were antihypertensive drug costs, antihypertensive drug cost per prescribing day, daily drug utilisation, average number of drugs per month, percentage of original drugs per prescription, drug overutilisation and prohibited combinations. Segmented regression analysis was used. Results: The drug price reduction reduced expenditure (US$-1.51, -10.2%), and the new guidelines reduced expenditures even more (US$ -2.13; -16.2%). These policies saved US$4.22 (28%) of antihypertensive drug costs per patient in December 2013 compared to March 2012. Drug price reduction policy was introduced in April 2012. We established the policy effect by comparing it before (March 2012) with after(21 months later-December 2012). The effects of the guidelines decreased expenditures, daily drug utilisation and the average number of drugs per month more than did the drug price reduction. Conclusions: Both policies saved money. The guidelines were more effective over time and had fewer side effects such as increasing daily drug utilisation and number of drugs than the effects of drug price reduction.

UR - http://www.scopus.com/inward/record.url?scp=84937199975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937199975&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2014-006940

DO - 10.1136/bmjopen-2014-006940

M3 - Article

C2 - 26179644

AN - SCOPUS:84937199975

VL - 5

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 7

M1 - e006940

ER -